AI204 therapeutic peptide vaccine: Began a Phase I trial

Immune Response Corp. (IMNR), San Diego Product: AI204 therapeutic peptide vaccine based on the VB17 receptor on autoreactive T cells Indication: Rheumatoid arthritis Status: Began a Phase I trial in ...